A frenzy of M&A deals hit the pharma sector in October, with Novo Nordisk, Bristol Myers Squibb, Eli Lilly and Novartis the big players that announced acquisitions.
In a strategic push to transform India’s pharmaceutical and biotech landscape, the government recently outlined and invited ...
US biopharma BridgeBio Pharma has presented data from the ATTRibute-CM study, showing that acoramidis significantly reduces ...
US obesity drug developer Metsera presented detailed results from two Phase IIb trials for its weight-loss drug candidate, ...
Spanish dermatology specialist Almirall has announced its financial results for the first nine months of 2025, presenting a ...
US clinical-stage genetic medicines company MeiraGTx Holdings saw its shares rise 15% to $9.74 pre-market today, as it ...
The US Food and Drug Administration (FDA) has extended by three months the review period for the supplemental New Drug Application (sNDA) for Boston, USA-based Rhythm Pharmaceuticals' Imcivree ...
Swiss pharma giant Roche today announced that the first Phase III (FENhance 2) of two pivotal, similarly-designed Phase III ...
A biotech company developing programmable mRNA therapeutics designed to control the location, timing, intensity and duration ...
US oncology company Summit Therapeutics and its partner Akeso have communicated results from the Phase III HARMONi-A trial - ...
French biotech EVerZom has signed its first research partnership with compatriot GENFIT to evaluate EViv, an exosome-based ...
Several regulators have released updates in recent days, ranging from drug approvals to procedural changes. A few approvals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback